Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) represents a significant advancement in the imaging of prostate cancer (PCa), yet its application in low- and intermedi...
This work was supported by the National Natural Science Foundation of China(General Program,No.81772722);Guangdong Province Science and Technology Planning Project(No.2017B020227008).
To efficiently remove all recurrent lymph nodes(rLNs)and minimize complications,we developed a combination approach that consisted of ^(68)Gallium prostate-specific membrane antigen(PSMA)ligand positron emission tomog...
The proPSMA trial is a Phase III multicentric trial that examined the role of gallium-68-prostate-specific membrane an tigen(PSMA)-p o sitro n em issio n tomography/computed tomography(PET/CT)scan versus conventional ...
Management of prostate cancer patients with biochemical relapse has long hampered due to insufficient capability to detect and localize recurrent disease with available imaging modalities such as CT, MRI, or bone scin...
Using conventional imaging modalities, it is difficult to detect recurrent lesions in prostate cancer patients who have undergone biochemical relapse, especially in patients with low prostate-specific antigen (PSA) ...
In the past 5 years, the treatment and understanding of metastatic castrate resistant prostate cancer (CRPC) have improved dramatically. Our understanding of the mechanisms of castration resistance has allowed for t...
Radioiodine therapy, the most effective form of systemic radiotherapy available, is currently useful only for thyroid cancer because of the thyroid-specific expression of the human sodium iodide symporter (hNIS). He...